<DOC>
	<DOC>NCT03065374</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of IMM-529 together with standard of care (SOC) in patients with Clostridium-difficile Infection.</brief_summary>
	<brief_title>Treatment for Clostridium-difficile Infection With IMM529</brief_title>
	<detailed_description>Subjects who provide voluntary written informed consent will be screened for eligibility. Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to participate. Eligible subjects will be randomized up to 3 weeks post diagnosis of Clostridium-difficile Infection given SOC initiated already. Each subject will return to the study clinic for assessment and required study procedures on Day 7, Day 14, Week 4, Week 8 and Week 12 post randomization. Treatment duration will be 28 days and follow up will last up to 12 weeks post randomization.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>1. Age â‰¥ 18 years 2. Unformed stools with a positive stool test for C. difficile by PCR (Polymerase chain reaction) and ELISA 3. up to 3 weeks of diagnosis with at least 20 subjects within 72 hours of diagnosis 4. Patient or legal representative must have read, understood, and provided written informed consent after the nature of the study has been fully explained. 1. History of chronic diarrheal illness such as ulcerative colitis or Crohn's disease 2. other etiology of diarrhea 3. Severe Complicated Disease 4. Severe C. difficile colitis with planned surgery in less than 24 hours. 5. Immunocompromised subjects due to malignancy or iatrogenic or other disease 6. Positive pregnancy test within 24 hours of study infusion or an unwillingness to undergo pregnancy testing in females of childbearing potential. Females capable of childbearing must agree not to become pregnant from the time of study enrollment until at least 28 days after completion of study treatment period. If a woman is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use 2 acceptable contraceptives (see section 7.4.1.) while participating in the study and for 28 days following the last dose of study drug. 7. Breastfeeding 8. Receipt of other investigational study agent within previous 30 days. 9. Cow milk allergy, lactose intolerance or any known or suspected hypersensitivity to study products 10. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the patient participating in the study or make it unlikely the patient could complete the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>